Literature DB >> 15976017

Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis.

Cleber E Teixeira1, Zhekang Ying, R Clinton Webb.   

Abstract

The Rho-kinase pathway mediates Ca2+ sensitization in the penile circulation, which maintains the penis in the flaccid state. We aimed to investigate the functional effect of a novel Rho-kinase inhibitor, H-1152 [(S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine], both in vitro and in vivo as well as to demonstrate the expression of Rho guanine nucleotide exchange factors (RhoGEFs) in the rat corpus cavernosum (CC), by using a semiquantitative reverse transcription-polymerase chain reaction assay to measure their mRNA expression. Cumulative addition of H-1152 (0.001-3 microM) or Y-27632 [0.01-30 microM; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide] caused sustained relaxations of precontracted CC strips, which were not affected by inhibition of the nitric oxide signaling pathway. Addition of H-1152 (0.1 microM), Y-27632 (1 microM), or sodium nitroprusside (SNP; 0.1 microM) caused rightward shifts in the curves to phenylephrine (PE), but it had little effect on the contractions mediated by electrical field stimulation (EFS). It is noteworthy that when H-1152 or Y-27632 was combined with SNP, a marked synergistic inhibition was noted both on PE- and EFS-induced contractions. Intraperitoneal administration of H-1152 (100 nmol/kg) had a discrete effect on mean arterial pressure and significantly enhanced erectile responses evoked by stimulation of the cavernous nerve. The mRNA expression for PDZ-RhoGEF, p115RhoGEF, and leukemia-associated RhoGEF in cavernosal segments was visualized by electrophoresis on agarose gel. The results indicate that H-1152 is a powerful Rho-kinase inhibitor, giving rise to its therapeutic potential in the treatment of erectile dysfunction. The regulator of G-protein signaling-containing RhoGEFs may represent key components of the molecular mechanisms associated with the abnormal function of the cavernosal smooth muscle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976017     DOI: 10.1124/jpet.105.086041

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Erectile function in two-kidney, one-clip hypertensive rats is maintained by a potential increase in nitric oxide production.

Authors:  A Elizabeth Linder; Anne M Dorrance; Thomas M Mills; R Clinton Webb; Romulo Leite
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 2.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

3.  The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat.

Authors:  George F Lasker; Edward A Pankey; Alexander V Allain; Subramanyam N Murthy; Johannes-Peter Stasch; Philip J Kadowitz
Journal:  Urology       Date:  2013-02       Impact factor: 2.649

4.  Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice.

Authors:  Fernanda B M Priviero; Li-Ming Jin; Zhekang Ying; Cleber E Teixeira; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2010-01-21       Impact factor: 4.030

Review 5.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay.

Authors:  Chris R Evelyn; Timothy Ferng; Rafael J Rojas; Martha J Larsen; John Sondek; Richard R Neubig
Journal:  J Biomol Screen       Date:  2009-02-04

7.  Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract.

Authors:  Cleber E Teixeira; Liming Jin; Fernanda B M Priviero; Zhekang Ying; R Clinton Webb
Journal:  Biochem Pharmacol       Date:  2007-06-07       Impact factor: 5.858

8.  Rho-Associated Kinase Inhibitors: Potential Future Treatments for Glaucoma.

Authors:  Ramin Daneshvar; Nima Amini
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.